LFCR 250117 5.00P (LFCR250117P5000) Stock Options, News & Quotes

0.10
+0.05+100.00%

15min DelayClose Dec 23 16:00 ET

0.10High0.10Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Dec 19 06:05

NEWS

$Lifecore Biomedical (LFCR.US)$
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
Thursday, 19th December at 7:00 am
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial
Lifecore to Leverage Differentiated Capabilities and Knowledge in Fill and Finish to Support Nirsum's NIH-Funded NRS-033 Development Program
CHASK...

Jaguar8

Nov 26 15:08

NEWS

$Lifecore Biomedical (LFCR.US)$
Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
Lifecore Biomedical has announced an amendment and extension of its asset-based lending revolving credit facility with BMO. The amendment extends the facility term by three years to November 2027, simplifies and reduces interest rates, and provides greater flexibility regarding covenants and reporting requirements. This follows the company's recent $24.3 million private placement financ...

Trytosaveabit

Oct 4 06:23

News

$Lifecore Biomedical (LFCR.US)$ Press Release: Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock
Dow Jones· 1 min ago

Jaguar8

Aug 26 16:24

NEWS ER

$Lifecore Biomedical (LFCR.US)$
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
Lifecore Biomedical (NASDAQ: LFCR) reported its fiscal year 2024 results, showing strong revenue growth of 24.2% to $128.3 million.
The company's CDMO business grew 27%, while its HA raw material manufacturing increased 18%.
Gross profit rose 49.5% to $41.9 million, with margin expanding to 32.6%.
Key highlights include:
Net income from con...

Moomoo AI

Nov 17, 2023 17:15

The Justice Department's decision could boost the practice of self-reporting in cases of corporate misconduct, given Lifecore's amicable resolution. This change is essentially incentivizing transparency and cooperation amongst corporations during bribery investigations.

Lifecore Biomedical Avoids U.S. Prosecution Over Alleged Mexico Bribes -- WSJ